Erlocip 100 MG Tablet contains Erlotinib 100mg, providing a dose-reduced erlotinib option in the Erlocip brand for patients requiring toxicity-based dose modification during NSCLC treatment.

How It Works: Erlotinib inhibits EGFR tyrosine kinase activity, disrupting the RAF-MEK-ERK and AKT signaling cascades that promote cancer cell proliferation and survival in EGFR-mutated non-small cell lung tumors.

Common Uses: Dose-adjusted EGFR-mutant NSCLC therapy, erlotinib maintenance after platinum chemotherapy, and pancreatic cancer combination protocols.

Administration: Take on an empty stomach at a consistent time each day. Swallow whole with water. Do not crush or split tablets.

Storage: Store below 25°C. Keep in original blister packaging away from moisture. Store out of reach of children.

Disclaimer: This product requires a valid prescription. Consult a licensed oncologist before use. This information is for educational purposes only.